AI 制药、基因编辑、细胞疗法和合成生物学在研发效率与监管合规之间加速迭代。
本周变化
+2.1%
最新更新
2026-06-08
情绪指数
76
行业热度
79
热度分数
79
综合行业热度与近期活跃度。
关键词增长
+2.2%
行业关键词周度变化均值。
基于本地 mock heat history 展示该行业最近周期 heatScore。
当前行业关键词热度、增长率与相对强度。
该行业最新情报摘要，包含周期、驱动因素、风险与短期展望。
生物科技关注点从平台叙事回到临床进展、可制造性和监管沟通，资本更看重里程碑兑现。
当前行业关键事件，按时间倒序排列。
平台企业开始用临床里程碑证明生成式研发效率。
Future Radar Mock Desk
当前行业相关 signals，可按类型过滤并按重要性排序。
当前行业的结构化报告仍保留在详情页底部，独立报告详情页将在 Stage 4.0 后续轮次接入。
资本关注度
73
最近热度样本中的资本活跃强度。
技术突破度
80
研究、产品和技术活动综合信号。
政策关注度
68
政策信号与市场活动的合成读数。
风险等级
46
高影响、安全与趋势风险的综合暴露。
建议关注临床里程碑、自动化生产设备订单和合成生物材料的吨级成本曲线。
脱靶评估和长期随访计划被更早纳入开发路径。
Future Radar Mock Desk
封闭式设备和批次质控数据成为产能扩展关键。
Future Radar Mock Desk
表达量、稳定性和纯化难度被提前纳入评分。
Future Radar Mock Desk
候选分子生成流程开始闭环接收实验结果。
Future Radar Mock Desk
行业内具有代表性的公司、研究机构和生态节点。
Medical device maker iRhythm has been hit by a cyberattack, but the company said the incident has not affected its core products, operations or ability to meet patient needs.
AI drug design specialist Protillion has inked a $510 million biobucks collaboration and license agreement with Merck & Co. that brings together Protillion’s platform and Merck’s drug discovery expertise.
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
Adaptive Biotechnologies is planning to separate its drug discovery and diagnostics businesses, outlining its intent to evaluate “strategic and structural alternatives” for the medicine wing of the company
Edgewise Therapeutics has reported phase 2 data on its cardiomyopathy prospect, keeping the biotech on track to start pivotal development of a would-be challenger to Bristol Myers Squibb and Cytokinetics.
Eli Lilly is taking another shot at the pain market, continuing a recent M&A binge that shows no signs of slowing down.
As biopharma companies of all stripes devote more time and attention to AI-based drug discovery and development, healthcare PE firm Altaris is bolstering its presence in the field through M&A.
Jazz Pharmaceuticals is looking to bolster its oncology research bona fides via a partnership with AbCellera to discover and develop T-cell-engaging (TCE) antibodies that could result in up to $820 million in biobucks for each program that Jazz options.
With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is back to full health.”
With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’ first mRNA-based influenza vaccine are heading into a critical test this week.
The FDA has pulled a U-turn on uniQure’s Huntington’s disease gene therapy, giving the biotech the OK to file for accelerated approval after previously demanding data from another trial.
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
F2G and Shionogi have released phase 3 data for the oral antifungal drug olorofim, demonstrating its non-inferiority compared with an existing drug for invasive aspergillosis.
John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of the antibody-drug conjugate specialist’s new five-year plan, which aims to lay the groundwork for Daiichi to become a global top 5 oncology company by 2035.
Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention.
Biogen has struck a backloaded, $1 billion deal to buy RayThera, snagging a pipeline of anti-inflammatory drug candidates led by a prospect on the cusp of clinical development.
Novocure’s tumor-treating electric fields device missed its primary endpoint in a late-stage glioblastoma trial.
Kardigan’s IPO haul has come in 14% above expectations, grossing $400 million after the cardiovascular disease biotech upsized the offering and hit the top end of its target range.
Innoviva has revealed the next steps for Langer Lab assets it rescued from Lyndra Therapeutics’ collapse, launching Nortiva Bio to develop long-acting oral medicines and pursue drug development alliances.
As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its bid to expand the reach of its mRNA platform to the massive influenza vaccination market.
In another biotech born out of China’s “NewCo” model, cAMPfield Therapeutics has launched with a $180 million series A and a focus on oral medicines for inflammatory diseases.
Zoll Medical, the maker of devices and software focused on cardiopulmonary and respiratory conditions, was slammed in an FDA warning letter that outlined numerous quality control and medical device reporting violations.
Biotech and biopharma companies choose names that cluster around certain letters in the alphabet - here's what they are, and why it happens. The post The Naming Patterns Behind 12,000 Biotech Companies appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibit...
This week we preview the BIO International Convention, starting next week in San Diego. The post BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts...
We have curated a list of in vivo CAR T biotechs in preclinical and clinical stages that you should keep an eye out for. The post Eight in vivo CAR T biotechs to follow closely appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links ma...
Explore how viral vector CDMOs improve late-stage cell and gene therapy success by reducing risk, variability, and complexity. The post Viral vector production: How CDMOs influence late-stage development success appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictl...
Find out more about the wave of biotech rebranding and why a growing number of companies are choosing this path to start afresh. The post New names, new narratives: Why biotechs decide to rebrand appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Ex...
Not so long ago, DIY biology mostly meant extracting DNA from strawberries or growing mold in a petri dish for a school science project. Those experiments are still around, but the world of amateur biology has evolved considerably over the past decade.  Today, a growing network of community biology labs and citizen scientists is making biotechnology more […] The post DIY biology experiments: h...
Today we’re diving into the world of corticosteroids and hormonal therapies, essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine disorders. The post Advancing corticosteroids and hormonal therapies for supply and scale appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written perm...
Discover Daiichi Sankyo's pipeline strategy, including how it aims to become a top-five global oncology company by 2035. The post How Daiichi Sankyo aims to become a top five oncology player by 2035 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited....
Find out about some early-stage technologies in neurology that aim to go beyond amyloid, dopamine, and what has dominated the field. The post Beyond amyloid and dopamine: emerging technologies reshaping neurology appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strict...
Spain is emerging as a European pharma and biotech hub, driven by scientific excellence, clinical trial leadership, innovation, and investor appeal. The post Pharma in Spain: why global investors and innovators are moving in appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or own...
There were seven multibillion-dollar acquisitions that occurred in May 2026, although it was a quieter month on the biotech deals front. The post Top biotech deals in May 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may...
Discover 8 key oncology deals that have been made so far in 2026, spotlighting where industry leaders are betting big. The post Eight oncology deals in 2026 spotlight where industry leaders are betting big appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly proh...
Selected signals indicate a biotech sector balancing technical expansion with operational pressure. Merck’s $510M biobucks collaboration with Protillion highlights continued investment in AI-enabled data generation and drug discovery platforms, while iRhythm’s cyberattack underscores persistent cybersecurity exposure around patient data and connected medical operations. At the same time, reported workforce reductions at enGene and Neumora point to ongoing cost discipline and restructuring pressure across biotech organizations. These signals collectively suggest that biotech technical strategy this week is shaped by three linked priorities: extracting value from data-generation platforms, protecting sensitive health data and operations, and preserving capital efficiency during workforce contraction.